Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty
Author(s) -
David R. Anderson,
Michael Dunbar,
John Murnaghan,
Susan R. Kahn,
Peter L. Gross,
Michael Forsythe,
Stéphane Pelet,
Winfield S. Fisher,
Étienne L. Belzile,
Sean Dolan,
Mark Crowther,
Éric Bohm,
Steven J. MacDonald,
Wade Gofton,
Paul J. Kim,
David J. Zukor,
Susan Pleasance,
Pantelis Andreou,
Steve Doucette,
Chris Theriault,
Abongnwen Abianui,
Marc Carrier,
Michael J. Kovacs,
Marc Rodger,
Doug Coyle,
Philip S. Wells,
PascalAndré Vendittoli
Publication year - 2018
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1712746
Subject(s) - rivaroxaban , medicine , aspirin , deep vein , pulmonary embolism , venous thrombosis , venous thromboembolism , arthroplasty , thrombosis , clinical trial , apixaban , hip arthroplasty , surgery , anesthesia , warfarin , atrial fibrillation
Clinical trials and meta-analyses have suggested that aspirin may be effective for the prevention of venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism) after total hip or total knee arthroplasty, but comparisons with direct oral anticoagulants are lacking for prophylaxis beyond hospital discharge.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom